ASArdaman Shergill

Ardaman Shergill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ardaman Shergill has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0

    by Rachna T. Shroff, Erin B. Kennedy, Ashley Efrain Alarcon Rozas, Rajiv Agarwal, Melinda Bachini, Marina Baretti, Gagandeep Brar, Allen L. Cohn, Madhu Eluri, Olumide B. Gbolahan, et al.

    PURPOSE: This living guideline provides recommendations for liquid biopsy and treatment of patients with advanced biliary tract cancer . METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for liquid biopsy and systemic therapy for patients with advanced biliary tract cancer. RESULTS: Six studies provided estimates of concordance between liquid biopsy and tissue biopsy. Nine RCTs were included in the evidence base for first-line therapy. One phase III RCT and four phase II RCTs were included in the evidence for second-line chemotherapy. Eleven single studies or reviews supported biomarker-specific second-line therapy recommendations. RECOMMENDATIONS: Testing with broad-based tissue DNA and RNA NGS testing to determine the presence of targetable biomarkers is recommended at the time of diagnosis at any stage. Liquid biopsy with plasma is generally recommended only when tissue biopsy is unavailable. As first-line therapy for patients with pMMR/MSS advanced BTC, immune checkpoint inhibitors (ICIs) plus chemotherapy is recommended. Options for patients with advanced BTC who are not candidates for ICIs are included in the guideline. Pembrolizumab monotherapy is an option for patients with dMMR/MSI-H advanced BTC. For patients with disease progression on first-line treatment and who have no identified biomarkers, FOLFOX with active symptom control, or active symptom control alone are recommended; options for patients who are ineligible for oxaliplatin-based chemotherapy are included in the guideline. Second-line therapy options are recommended for patients with dMMR/MSI-H, IDH1 mutations, FGFR2 fusions or rearrangements, BRAF V600E mutations, HER2 overexpression, RET, NTRK1/2/3, or NRG1 fusions. Additional information is available at https://ascopubs.org/guidelines/living-guidelines

  • Open Access

    Patterns of Patient-Reported Awareness About Early-Onset Cancer-Related Infertility Risk

    by Allison D. Morris, Samantha R. Keller, Rachel A. Francis, Ariana von Lersner, Zoe Finer, Heath C. Tolliver, Allison Rosen, Megan Scherer, Alexandra C. Sundermann, Ardaman Shergill, et al.

    PURPOSE: Reproductive care—including discussions about cancer-related infertility risk—is part of the recommended standard of care for all patients with cancer. Despite rising cancer incidence among adults younger than 50 years (early-onset), the evaluation of patients' knowledge about cancer-related infertility risk is limited. We characterized factors associated with lack of awareness of potential cancer-related infertility risk as reported by patients with early-onset cancer. PATIENTS AND METHODS: Using data from the Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study, we identified individuals diagnosed with a first primary early-onset cancer between 2006 and 2021. Awareness of potential cancer-related infertility risk was determined using questionnaires. Logistic regression models were fitted to examine associations between a lack of awareness of cancer-related infertility risk and patient-level factors. RESULTS: Among 636 patients, 28.9% (n = 184) reported never being told that their cancer treatments may affect their fertility. Patients who were aware of a potential cancer-related infertility risk had heard this information, on average, from two unique sources (mean = 2.2, std = 1.3)—with 90.1% of all sources derived from clinical interactions/settings. Patients who self-identified with a racial ethnic minority (REM) population—inclusive of African American/Black, American Indian, Asian, Hispanic/Spanish/Latino/a/x, Middle Eastern or North African, or multiple races—were nearly twice as likely to report an unawareness of infertility risk compared with patients who identified as non-Hispanic White after adjusting for diagnosis age and year, sex, insurance coverage, marital status, and pregnancy history (odds ratio, 1.70 [95% CI, 1.05 to 2.74]; P = .03). CONCLUSION: Three in every 10 patients with early-onset cancer reported never having been told that cancer treatments may affect their fertility. Individual factors contributed to differences in patients' knowledge of potential cancer-related infertility risk. Further study is needed to address this care gap among patients and providers to deliver concordant, high-quality reproductive and oncology care to this growing population.

  • PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma

    by Princy Gupta, Rushabh Gujarathi, Lu Qiao, Elizabeth L. Godfrey, Kurt S. Schultz, Samuel D. Butensky, Justin M. Bader, Raghav Sundar, Michael Cecchini, Ardaman Shergill, et al.

    PURPOSE: Approximately one in three patients with appendiceal cancer (AC) is diagnosed before age 50 years. Early-onset appendiceal cancer (EOAC) exhibits distinct clinicopathologic and demographic features compared with late-onset disease, suggesting potential biological differences. However, the molecular differences remain poorly understood. This study aims to compare EOAC and late-onset AC (LOAC, ≥50 years) mutational profiles and evaluate their impact on overall survival (OS). METHODS: A retrospective analysis was conducted using the Memorial Sloan Kettering—Metastatic Events and Tropisms database. Patients were stratified by age at the time of surgery into EOAC and LOAC groups. Logistic regression was used to assess differences in mutational profiles between these two groups. Findings were validated using data from the American Association for Cancer Research Genomics Evidence Neoplasia Information Exchange project. Kaplan-Meier survival analysis and multivariable Cox proportional hazard models were used to evaluate associations with survival. RESULTS: The study included 200 patients with appendiceal adenocarcinoma (median age: 55 years, IQR, 47-68), of whom 70 (35%) had EOAC and 130 (65%) had LOAC. Patients with EOAC had higher odds of harboring PIK3CA mutations compared with LOAC (17.1% v 7.7%; odd ratio, 2.65; P = .04), which was consistent when combined with the GENIE data set (12.3% v 5.9%; P < .01). PIK3CA mutations were exclusively observed in patients with metastatic disease (11.8%) and were more common in adenocarcinoma not otherwise specified (NOS) than mucinous tumors (63.6% v 36.4%; P = .04). In multivariable analysis, PIK3CA mutations were independently associated with worse OS (hazard ratio, 2.62 [95% CI, 1.32 to 5.20]; P < .01). CONCLUSION: PIK3CA mutations are more common in EOAC and independently associated with worse OS. These findings suggest incorporating PIK3C A mutation status into prognostic assessments and warrant further investigation of PIK3CA inhibitors as a potential therapeutic strategy for appendiceal adenocarcinoma.


  • Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

    by Erica S. Tsang, Qian Shi, Ken Olive, Eric Collisson, Jesse G. Dixon, Mike Cusnir, Rafael Winograd, Gregory P. Botta, Raymond Wadlow, Ardaman Shergill, et al.


  • Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement

    by Elizabeth L. Godfrey, Forest Mahoney, Varun V. Bansal, David G. Su, David N. Hanna, Felipe Lopez‐Ramirez, Ekaterina Baron, Kiran K. Turaga, Al B. Benson, James Cusack, et al.

    Background: Appendiceal tumors comprise a heterogeneous group of tumors that may be localized or disseminated throughout the peritoneum. Limited high‐quality clinical data exist, and many practices have been extrapolated from colorectal cancer without validation in appendiceal cohorts. There are many controversies regarding the treatment of appendiceal tumors, and practices vary widely between centers and care settings. A national consensus update of best management practices for appendiceal malignancies was performed to better standardize care.Methods: The 2018 Chicago Consensus guideline was updated through a modified Delphi consensus performed over two rounds using nationally circulated surveys. Supporting evidence was evaluated using rapid systematic reviews. Key systemic therapy concepts were summarized by content experts.Results: Most supporting literature consists of observational studies, but high‐quality studies increasingly are becoming available to drive management. Two consensus‐based pathways were generated for localized appendiceal tumors: one for epithelial mucinous neoplasms and another for appendiceal adenocarcinoma. Of 138 participants responding in the first round, 133 (96%) engaged in the second round. Greater than 90% consensus was achieved for all pathway blocks. Key points include minimizing intervention invasiveness when permitted by pathologic classification and margin status and determining which margin and pathologic findings are indications for consideration of cytoreduction with or without intraperitoneal chemotherapy. Surveillance and systemic therapy recommendations are also presented.Conclusions: With growing but still primarily observational evidence currently dictating care, these consensus recommendations provide expert guidance in the treatment of appendiceal tumors without peritoneal involvement.


  • Consensus guideline for the management of colorectal cancer with peritoneal metastases

    by Kurt S. Schultz, Varun V. Bansal, Michael M. Wach, Neal Bhutiani, Frederick A. Godley, Jaeyun (Jane) Wang, Muhammad Talha Waheed, Joanna T. Buchheit, Emily Papai, Susan Campbell, et al.

    The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metastases (CRC‐PM). An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique. Two rounds of voting were performed to assess agreement levels on two clinical management pathways regarding synchronous and metachronous CRC‐PM. Supporting evidence was evaluated via rapid literature reviews. The overall level of evidence was low in the existing literature. Of 145 participants in the first round, 136 (96.8%) responded in the second round. Over 90% consensus was achieved in most pathway blocks. For both pathways, early referral to a peritoneal surface malignancy center should be made for patients with CRC‐PM. For the synchronous pathway, upfront cytoreductive surgery was deemphasized in favor of systemic therapy. For the metachronous pathway, risk stratification via clinical and pathological features was revised. For both pathways, surveillance strategies were added, including only a weak recommendation for circulating tumor DNA testing, given limited evidence of its utility in detecting and monitoring PM. The consensus‐driven clinical pathways provide valuable guidance for the management of CRC‐PM. There remains a need for high‐quality evidence and prospective multicenter trials in this domain.